anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine for treating gastroenteropathy. The traditional Chinese medicine is characterized by comprising 10-12 weight parts of haw, 5-8 weight parts of red yeast rice, 6-9 weight parts of radish seed, 3-5 weight parts of coptis, 10-12 weight parts of gynostemma pentaphylla, 10-12 weight parts of mango leaf, 3-5 weight parts of sweet osmanthus, 3-5 weight parts of pseudo-ginseng, 10-12 weight parts of red sage root, 8-10 weight parts of bighead atractylodes rhizome, 6-9 weight parts of fructus amomi, 10-12 weight parts of polyalthia root, 10-12 weight parts of periploca forrestii, 10-12 weight parts of pilose asiabell root, 12-15 weight parts of rose root and 9-12 weight parts of Chinese chestnut leaf. Red yeast rice, haw, radish seed, bighead atractylodes rhizome and fructus amomi have effects of warming stomach and invigorating spleen. Gynostemma pentaphylla and coptis have effects of clearing heat, removing toxins, killing germs and removing pathogenic factors. Pilose asiabell root can promote human body function recovery. Pseudo-ginseng can repair of stomach and intestine. The traditional Chinese medicine realizes simultaneous treatment of principal and subordinate symptoms and has good effects of treating gastroenteropathy.
<P>PROBLEM TO BE SOLVED: To provide a system capable of conveniently delivering an imaging protocol with maintaining a security.  <P>SOLUTION: A comedical in a protocol publication medical institution 6 develops a new imaging protocol, and transmits the imaging protocol to a protocol delivery institution 2 via a leased line. The protocol delivery institution 2 develops a publication package including identification information of the imaging protocol and an address of the protocol delivery institution 2. A protocol publication institution 8 releases Web pages created with the publication package on the Internet. A comedical in a protocol using medical institution 9 refers to the Web pages, designates a imaging protocol of its choice, and a delivery reservation is transmitted to the protocol delivery institution 2 via the Internet. The protocol delivery institution 2 transmits the designated imaging protocol to a medical diagnostic imaging apparatus 11 via the leased line.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The efficacy of ZIPSOR in adults was demonstrated in two multicenter, randomized, double-blind, placebo- controlled, parallel arm, multiple-dose clinical trials comparing ZIPSOR 25 mg and placebo in patients with pain following bunionectomy with osteotomy. Once patients met the criteria for randomization (pain intensity ≥4 on a 0-10 numerical pain rating scale) they received their initial dose of study medication followed by a remedication dose when requested by the patient, and were then dosed every six hours over four days. Pain intensity was recorded at 3 and 6 hours postdose during the fixed dosing period. In Study 1, mean baseline pain intensity scores were 6.9 in the ZIPSOR group (range: 4 – 10) and 7.3 in the placebo group (range: 4 – 10). In both studies, patients treated with ZIPSOR had a lower mean pain intensity score over the 48-hour inpatient period following the first remedication dose (see Figure 1). The median time to onset of pain relief was less than one hour for ZIPSOR 25 mg across the clinical trials.

The results were similar in Study 2.

Figure 1 Mean Pain Intensity Scores at the Midpoint and End of Each Dose Interval in Postbunionectomy Pain Study 1
Sepsis is a life-threatening syndrome resulting from an imbalanced immune response to severe infections. Despite advances in nanomedicines, effective treatments for sepsis are still lacking. Herein, vancomycin free base (VCM)-loaded dual functionalized biomimetic liposomes based on a novel TLR4-targeting peptide (P3) and hyaluronic acid (HA) (HA-P3-Lipo) were developed to enhance sepsis therapy. The nanocarrier revealed appropriate physicochemical parameters, good stability, and biocompatibility. The release of VCM from HA-P3-Lipo was found to be sustained with 76 % VCM released in 48 h. The biomimicry was elucidated by in silico tools and MST and results confirmed strong binding between the system and TLR4. Furthermore, HA-P3-Lipo revealed 2-fold enhanced antibacterial activity against S. aureus, sustained antibacterial activity against MRSA over 72 h and 5-fold better MRSA biofilm inhibition compared to bare VCM. Bacterial-killing kinetics and flow cytometry confirmed the superiority of HA-P3-Lipo in eliminating MRSA faster than VCM. The in vivo potential of the nanocarrier was elucidated in an MRSA-induced sepsis mice model, and the results confirmed the superiority of HA-P3-Lipo compared to free VCM in eliminating bacteria and down-regulating the proinflammatory markers. Therefore, HA-P3-Lipo exhibits potential as a promising novel multi-functional nanosystem against sepsis and could significantly contribute to the transformation of sepsis therapy.
Implementations described and claimed herein provide systems and methods for generating an optimized treatment experience for a patient. In one implementation, patient experience data is captured using at least one patient experience device. The patient experience data corresponds to a patient experience factor for the patient. A current level of the patient experience factor is determined using a patient experience processing system. The current level of the patient experience factor is determined based on the patient experience data. A customized therapy for the patient is generated based on the current level of the patient experience factor. The customized therapy is an alternative treatment to a drug therapy administration. An administration of a patient treatment experience is generated based on the customized therapy. The patient treatment experience is generated using the at least one patient experience device and includes one or more of patient sense stimulation and patient cognitive stimulation.
Posiphen®, which was discovered by the US National Institute on Aging (NIA) is a small, orally active, experimental drug that specifically inhibits the synthesis of amyloid precursor protein (APP), Tau and α-Synuclein. It is distinct from other Alzheimer's disease drugs currently in development, because it inhibits the formation of several toxic proteins, rather than removing individual toxic protein after they are produced. Posiphen has potential utility as a disease modifying treatment for AD. The present study will confirm the pharmacokinetics (PK) of Posiphen and its metabolites in plasma and cerebral spinal fluid (CSF). It will also measure the effects of a 23-25 day treatment period with Posiphen on the CSF and plasma levels of a number of biomarkers, inflammatory factors and control proteins. It will also expand the safety data in humans by extending the treatment period from 10 days to a treatment period from 23-25 days. In addition, this study will measure concentrations of various soluble biomarkers in CSF and use the SILK™ assay methods to directly measure the effect of Posiphen on the fractional synthesis rate of Aβ40 in CSF, which will help guide the further development of Posiphen and determine the feasibility of SILK™ in a multicenter trial.
BYDUREON BCISE may induce nausea and vomiting with transient hypovolemia and may worsen renal function. There have been postmarketing reports of altered renal function with exenatide, including increased serum creatinine, renal impairment, worsened chronic renal failure and acute renal failure, sometimes requiring hemodialysis or kidney transplantation. Some of these events occurred in patients receiving one or more pharmacologic agents known to affect renal function or hydration status such as angiotensin converting enzyme inhibitors, nonsteroidal anti-inflammatory drugs, or diuretics. Some events occurred in patients who had been experiencing nausea, vomiting or diarrhea, with or without dehydration. Reversibility of altered renal function has been observed in many cases with supportive treatment and discontinuation of potentially causative agents, including BYDUREON (exenatide) for extended-release injectable suspension. BYDUREON BCISE is not recommended for use in patients with an eGFR below 45 mL/min/1.73 m2[see Use in Specific Populations (8.6)].
The invention relates to an integrated novel form preparation technology for Sisheng Wan and a production method thereof. The effective components of the Sisheng Wan comprise the following raw materials in parts by weight: 9 parts of raw lotus leaf, 9 parts of raw artemisia leaf, 12 parts of raw platycladus orientalis and 15 parts of dried rehmannia root. The production process of the Sisheng Wan comprises the steps of supersonic airflow pulverizing, alcohol water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spraying and drying, nanometer grinding, uniform high-pressure emulsification, nano particle preparation and the like. According to the invention, the multi-synergism, multi-target and other advantages embodied by a nano-carrier coupling technique are attached to apply. After the Sisheng Wan is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The Sisheng Wan can be taken by internally and externally feeding and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of human body. In addition, the Sisheng Wan can be prepared into films and transdermal agents which are respectively attached to different parts of human body according to the midnight-noon ebb-flow and qi and blood flowing rule of human body and can be directly absorbed through skin.
BACKGROUND: Phyllodes tumours of the breast are rare, and their treatment is still subject to discussion. They are classified as benign, borderline, or malignant based on histopathological characteristics of the stroma. This study demonstrates 10 years' experience in diagnosis and management of malignant phyllodes.
METHODS: All patients referred for discussion at our sarcoma multidisciplinary team meeting from 2003 to 2013 with a diagnosis of malignant phyllodes were identified. Patient demographics, biopsy details, excision extent, final pathology, reconstruction, adjuvant treatment, recurrence and overall survival were assessed.
RESULTS: Thirty patients were identified over the 10 year period. Eight (26.7 %) had their diagnosis upgraded to malignant phyllodes on completion excision, compared to initial biopsy. Nine (30 %) had breast surgery elsewhere as definitive treatment before referral to our service. Four of these (44.4 %) required more extensive excision and three developed metastases (33.3 %) and died. Twenty-one patients had primary surgery through our service and three (14.3 %) died from disease. Overall, 13 patients had radical mastectomy, 92.3 % with adequate margins (>1 cm histologically) and no local recurrence, 9 simple mastectomy 22.2 % with adequate margins and 1 local recurrence and 8 wide local excision with 37.5 % adequate margins and 1 local recurrence.
CONCLUSION: For malignant phyllodes patients, the best chance to reduce recurrence and improve survival is adequate excision and radical mastectomy should be considered. For borderline lesions, consideration should be given for referral to a specialist centre and we recommend delayed reconstruction, because of the chance of histological upgrade to malignancy.
Pregnancy Category C 

Atovaquone: Atovaquone was not teratogenic and did not cause reproductive toxicity in rats at doses up to 1,000 mg/kg/day corresponding to maternal plasma concentrations up to 7.3 times the estimated human exposure during treatment of malaria based on AUC. In rabbits, atovaquone caused adverse fetal effects and maternal toxicity at a dose of 1,200 mg/kg/day corresponding to plasma concentrations that were approximately 1.3 times the estimated human exposure during treatment of malaria based on AUC. Adverse fetal effects in rabbits, including decreased fetal body lengths and increased early resorptions and post-implantation losses, were observed only in the presence of maternal toxicity. 

In a pre- and post-natal study in rats, atovaquone did not produce adverse effects in offspring at doses up to 1,000 mg/kg/day corresponding to AUC exposures of approximately 7.3 times the estimated human exposure during treatment of malaria. 

Proguanil: A pre- and post-natal study in Sprague-Dawley rats revealed no adverse effects at doses up to 16 mg/kg/day of proguanil hydrochloride (up to 0.04-times the average human exposure based on AUC). Pre- and post-natal studies of proguanil in animals at exposures similar to or greater than those observed in humans have not been conducted. 

Atovaquone and Proguanil: The combination of atovaquone and proguanil hydrochloride was not teratogenic in pregnant rats at atovaquone:proguanil hydrochloride (50:20 mg/kg/day) corresponding to plasma concentrations up to 1.7 and 0.1 times, respectively, the estimated human exposure during treatment of malaria based on AUC. In pregnant rabbits, the combination of atovaquone and proguanil hydrochloride was not teratogenic or embryotoxic to rabbit fetuses at atovaquone:proguanil hydrochloride (100:40 mg/kg/day) corresponding to plasma concentrations of approximately 0.3 and 0.5 times, respectively, the estimated human exposure during treatment of malaria based on AUC. 

There are no adequate and well-controlled studies of atovaquone and/or proguanil hydrochloride in pregnant women. Atovaquone and proguanil hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. 

Falciparum malaria carries a higher risk of morbidity and mortality in pregnant women than in the general population. Maternal death and fetal loss are both known complications of falciparum malaria in pregnancy. In pregnant women who must travel to malaria-endemic areas, personal protection against mosquito bites should always be employed in addition to antimalarials. [See Patient Counseling Information ( 17).] 

The proguanil component of atovaquone and proguanil hydrochloride acts by inhibiting the parasitic dihydrofolate reductase [see Clinical Pharmacology ( 12.1)] . However, there are no clinical data indicating that folate supplementation diminishes drug efficacy. For women of childbearing age receiving folate supplements to prevent neural tube birth defects, such supplements may be continued while taking atovaquone and proguanil hydrochloride.
The prevalence of childhood obesity is rapidly increasing. Therefore, gaining more information on the role of environmental parameters is key. With overexpression of leptin (encoded by LEP) in obesity, LEP methylation might be altered by environmental exposures. This study aims to assess effects of ambient air pollution and nearby greenness on obesity-related growth and LEP methylation in early childhood. We monitored 120 mother-child pairs from conception until the age of five. Buccal swabs and anthropometric measurements of the children were taken at six months, one year, and five years old. Buccal DNA was extracted to determine LEP methylation levels. Estimates of air pollution and nearby greenness were calculated using high-resolution models. Effects of air pollution and nearby greenness on growth or LEP methylation were investigated using linear mixed effects models. Positive associations were shown for air pollution between conception and age one on impedance in six-month-olds and one-year-olds in the crude model. PM with aerodynamic diameter ≤10 (PM10) and ≤2.5 μm (PM2.5) positively associated with waist-hip-ratio and waist circumference at age five in the fully adjusted model. In early childhood, closest distance to forest negatively, and urban green and forest positively associated with weight-for-length, body mass index, and fat percentage in five-year-olds in the fully adjusted model. No significant associations for noise, and walkability on growth were seen. Negative associations were shown for smaller green clusters and positive associations for greater green clusters on LEP methylation in one-year-olds. For forest distance, walkability, noise, or all green on LEP methylation, no significant associations were found. Evidence is provided that ambient air pollution might have a significant effect on impedance and waist-hip-ratio, suggesting an increased risk of childhood obesity. Based on LEP methylation, greater green clusters might associate with a decreased risk of childhood obesity, while smaller green clusters showed the opposite.
Background: In the absence of head-to-head comparative data from randomized controlled trials, indirect treatment comparisons (ITCs) may be used to compare the relative effects of treatments versus a common comparator (either placebo or active treatment). For acute pain management, the effects of oliceridine have been compared in clinical trials to morphine but not to fentanyl or hydromorphone. Aim: To assess the comparative safety (specifically differences in the incidence of nausea, vomiting and opioid-induced respiratory depression [OIRD]) between oliceridine and relevant comparators (fentanyl and hydromorphone) through ITC analysis. Methods: A systematic literature review identified randomized clinical trials with oliceridine versus morphine and morphine versus fentanyl or hydromorphone. The ITC utilized the common active comparator, morphine, for the analysis. Results: A total of six randomized controlled trials (oliceridine - 2; hydromorphone - 3; fentanyl - 1) were identified for data to be used in the ITC analyses. The oliceridine data were reported in two studies (plastic surgery and orthopedic surgery) and were also reported in a pooled analysis. The ITC focused on nausea and vomiting due to limited data for OIRD. When oliceridine was compared with hydromorphone in the ITC analysis, oliceridine significantly reduced the incidence of nausea and/or vomiting requiring antiemetics compared with hydromorphone (both orthopedic surgery and pooled data), while results in plastic surgery were not statistically significant. When oliceridine was compared with hydromorphone utilizing data from Hong, the ITC only showed a trend toward reduced risk of nausea and vomiting with oliceridine that was not statistically significant across all three comparisons (orthopedic surgery, plastic surgery and combined). An ITC comparing oliceridine with a study of fentanyl utilizing the oliceridine orthopedic surgery data and combined orthopedic and plastic surgery data showed a trend toward reduced risk that was not statistically significant. Conclusion: In ITC analyses, oliceridine significantly reduced the incidence of nausea and/or vomiting or the need for antiemetics in orthopedic surgery compared with hydromorphone and a non-significant trend toward reduced risk versus fentanyl.
PURPOSE:To obtain an antithrombotic medicine exhibiting excellent antithrombotic action and capable of using as a medicine for preventing and treating vascular diseases such as cardiac infarction and diabetic complication. CONSTITUTION:This antithrombotic medicine contains a 2,5-pyrrolidine-dione derivative of the formula (ring A is a trialkoxyphenyl; R<1> is a substitutive alkyl, a substitutive alkoxy, a substitutive amino or pyridinylcarbonyl) or its pharmacologically permissible salt, e.g. (3E,4E)-1-methyl-3-benzylidene-4-(3,4,5- trimethoxybenzylidene)-2,5-pyrrolidinedione as an active ingredient. The compound has excellent PA activity promoting action and PAT-1 activity inhibiting action and exhibits excellent antithrombotic action even in either of oral administration and parental administration. The dose of the compound is preferably 0.5-50mg/kg.day in oral administration and preferably 0.05-5mg/kg.day in parental administration. The antithrombotic medicine can be used also as a medicine for preventing reobstruction after percutaneous coronary artery forming operation or after thrombolytic therapy or a medicine for preventing and treating arteriosclerosis.
The cancer stem cell model hopes to explain solid tumour carcinogenesis, tumour progression and treatment failure in cancers. However, the cancer stem cell model has led to minimal clinical translation to cancer stem cell biomarkers and targeted therapies in solid tumours. Many reasons underlie the challenges, one being the imperfect understanding of the cancer stem cell model. This review hopes to spur further research into clinically translatable cancer stem cell biomarkers through first defining cancer stem cells and their associated models. With a better understanding of these models there would be a development of more accurate biomarkers. Making the clinical translation of biomarkers into diagnostic tools and therapeutic agents more feasible.
The present invention relates to a new specific medicine prepared from Chinese herbal medicines and used for curing rheumatic and rheumatoid osteoarthritis, which belongs to the technical field of Chinese base medicines. The specific medicine can effectively overcome the defects of the existing medicines in treatment. The specific medicine is mainly characterized in that the formula of the medicine uses silkworm, scorpion and pangolin for wind removal, spasmolysis, network vessel freeing and sputum elimination as main medicines and uses hinese ephedra, atractylodes rhizome, achyranthis bidentatae, licorice root, acanthopanax bark, frankincense and myrrh as auxiliary medicines. Firstly, the medicines are respectively processed, fine sprayed and placed in a container for sealing without air leakage. The medicine powder can be prepared into capsules, powder, medicinal granules, etc. The specific medicine is mainly used for curing rheumatic and rheumatoid osteoarthritis.
Resistance exercise that involves participating in activities similar to lifting weights that cause the participant to work specific muscles of your body, with activity progressing to 150 minutes per week. This can involve using weight training machines, elastic tubes that create resistance, or weights such a dumbbells. This will require the participant to attend one supervised session each week for a period of 12 months with the remaining sessions being performed on their own without supervision.
Semaglutide is a Glucagon-like peptide 1 (GLP-1) receptor agonist. It up regulates GLP-1, which reduces glucagon levels, increases satiety and - in some particular cases - increases insulin production. It will be subcutaneously injected weekly by participants at progressively increasing doses. Once the maximum tolerated dose is achieved, participants will begin the meal strategies.